logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Meitheal Pharmaceuticals expands portfolio with acquisition of CONTEPO™ (Fosfomycin for Injection) from Nabriva Therapeutics

Jul 18, 2024•over 1 year ago

Acquiring Company

Meitheal Pharmaceuticals

Acquired Company

Nabriva Therapeutics

ChicagoDublinBiopharmaPharmaceuticalBiotechnology

Description

Meitheal Pharmaceuticals, Inc. announces the acquisition of North America rights to CONTEPO™ (fosfomycin for injection) from Nabriva Therapeutics. This strategic addition to Meitheal's product portfolio aims to address the significant unmet need around increasing antibiotic resistance and to deliver a consistent supply of high-quality antibiotic to patients and providers in need of innovative options for drug-resistant urinary tract infections.

Company Information

Company

Meitheal Pharmaceuticals

Location

Chicago, Illinois, United States

About

Meitheal Pharmaceuticals, founded in 2017, is a privately held pharmaceutical company specializing in generic injectable products. Headquartered near Chicago, Illinois, Meitheal is backed by a seasoned management team and driven by a bold growth strategy. Through strategic global partnerships, the company is committed to delivering high-quality, reliable, and affordable injectable medications to healthcare providers across the United States.

Related People

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed